Celldex halts eczema drug development after trial failure; shares fall more than 3%
Key Facts
Celldex said on November 19 that it was halting development of barzolvolimab for atopic dermatitis after a Phase 2 study failed to meet its primary endpoint and key secondary endpoints. The company said the improvement recorded did not reach the threshold needed to justify further development of the drug for the disease. Its shares fell more than 3% in extended trading after the announcement, according to Reuters. The trial included 131 patients at 28 U.S. centers, randomly assigned in a 1:1:1 ratio to 150 mg and 300 mg doses or placebo. The placebo-controlled portion lasted 16 weeks, following an initial 450 mg loading dose and then doses every four weeks.
At week 16, average weekly itch fell 19.5% from baseline in the placebo group. The 300 mg group recorded a decline of 29.2%, while the decline was 16.2% with the 150 mg dose. However, the difference between the 300 mg dose and placebo was not statistically significant, with a p-value of 0.187. The comparison for the 150 mg dose had a p-value of 0.651, also not statistically significant. The itch data therefore did not give the company sufficient grounds to overcome the failure of the primary endpoint or continue the atopic dermatitis program.
The shortfall extended to other disease measures, with the change in the EASI eczema severity score showing no meaningful difference from placebo. The proportion of patients whose IGA score was 0 or 1 also showed no meaningful difference from placebo. Longer treatment did not produce additional improvement through week 32, according to the company statement. These results support the decision to halt development of the drug for this indication after the study failed to meet its primary or key secondary objectives. Celldex said mast cells contribute to atopic dermatitis but are not its primary driver, the company’s explanation for the program’s results.
Despite the efficacy shortfall, Celldex said barzolvolimab was well tolerated during the study. It also observed rapid and deep suppression of circulating tryptase with both doses, which the company said indicates systemic mast cell depletion. This result shows that the drug had a biological effect on the target associated with its mechanism of action, but that this was not accompanied by sufficient improvement in atopic dermatitis measures. The finding distinguishes evidence of an effect on tryptase from evidence of the clinical efficacy needed to continue development for this disease. The company therefore halted the atopic dermatitis program while keeping studies of the drug in other conditions in its clinical plan.
The decision to halt development for this indication does not mean barzolvolimab development is ending altogether; Celldex said it is continuing Phase 3 studies for chronic spontaneous urticaria, cold urticaria and symptomatic dermographism. It added that its cold urticaria and symptomatic dermographism studies are enrolling participants. The company expects to submit a biologics license application to the U.S. Food and Drug Administration for chronic spontaneous urticaria in 2027. It also said it would announce additional indications for the drug before the end of 2026. These clinical programs keep the drug’s development on track for other diseases, while the announced decision is limited to atopic dermatitis treatment.